Skip to Content

    Two drugs for hepatitis C, Harvoni and Sovaldi, helped sales top $7 billion during the final quarter of 2014 for this biopharma company.

    41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

    Company Information

    Location
    Foster City, CA
    Industry
    Pharmaceuticals
    Sector
    Health Care
    Fortune 500 Rank118
    Fortune 500 Profilehttp://fortune.com/fortune500/gilead-sciences-118/
    Current Streak1
    Years on List6
    CEO
    John C. Martin
    Websitehttp://www.gilead.com

    Revenue, Net Income

    Revenue Past Four Quarters27,485
    Net Income Past Four Quarters14,207

    Growth Rates

    EPS 3 yr Annual Growth Rate67%
    Rev 3 yr Annual Growth Rate43%
    Total Return 3 yr Annual Rate66%
    Beat S&P 3 yr Total Return?
    yes

    Rank

    EPS Growth Rank32
    Revenue Growth Rank21
    Total Return Rank
    21